SELE and acute myeloid leukemia: These findings highlight endothelial E-selectin as a promising therapeutic target, and are the basis for two phase III clinical trials to test the activity of GMI-1271 in combination with chemotherapy in adult AML patients (NCT03616470, NCT03701308).